Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging.

Autor:	Wada Y; Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan., Kidokoro K; Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan. Electronic address: k.kid@med.kawasaki-m.ac.jp., Kondo M; Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan., Tokuyama A; Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan., Kadoya H; Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan., Nagasu H; Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan., Kanda E; Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan., Sasaki T; Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan., Cherney DZI; Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada., Kashihara N; Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Jazyk:	angličtina
Zdroj:	Kidney international [Kidney Int] 2024 Sep; Vol. 106 (3), pp. 408-418. Date of Electronic Publication: 2024 May 25.
DOI:	10.1016/j.kint.2024.05.006
Abstrakt:	The mechanisms responsible for glomerular hemodynamic regulation with sodium-glucose co-transporter 2 (SGLT2) inhibitors in kidney disease due to type 2 diabetes remain unclear. Therefore, we investigated changes in glomerular hemodynamic function using an animal model of type 2 diabetes, treated with an SGLT2 inhibitor alone or in combination with a renin-angiotensin-aldosterone system inhibitor using male Zucker lean (ZL) and Zucker diabetic fatty (ZDF) rats. Afferent and efferent arteriolar diameter and single-nephron glomerular filtration rate (SNGFR) were evaluated in ZDF rats measured at 0, 30, 60, 90, and 120 minutes after the administration of a SGLT2 inhibitor (luseogliflozin). Additionally, we assessed these changes under the administration of the adenosine A1 receptor (A1aR) antagonist (8-cyclopentyl-1,3-dipropylxanthine), along with coadministration of luseogliflozin and an angiotensin II receptor blocker (ARB), telmisartan. ZDF rats had significantly increased SNGFR, and afferent and efferent arteriolar diameters compared to ZL rats, indicating glomerular hyperfiltration. Administration of luseogliflozin significantly reduced afferent vasodilatation and glomerular hyperfiltration, with no impact on efferent arteriolar diameter. Urinary adenosine levels were increased significantly in the SGLT2 inhibitor group compared to the vehicle group. A1aR antagonism blocked the effect of luseogliflozin on kidney function. Co-administration of the SGLT2 inhibitor and ARB decreased the abnormal expansion of glomerular afferent arterioles, whereas the efferent arteriolar diameter was not affected. Thus, regulation of afferent arteriolar vascular tone via the A1aR pathway is associated with glomerular hyperfiltration in type 2 diabetic kidney disease. (Copyright © 2024 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu